Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance.

@article{Lee2016HippoPE,
  title={Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance.},
  author={Jeong Eun Lee and Hee Sun Park and Dahye Lee and Geon Wook Yoo and Tackhoon Kim and Haeyon Jeon and Min-Kyung Yeo and Chiyoung Lee and Jae Young Moon and Sung Soo Jung and Ju Ock Kim and Sun Young Kim and Dong Il Park and Yeon Hee Park and Jae Cheol Lee and In Jae Oh and Dae Sik Lim and Chaeuk Chung},
  journal={Biochemical and biophysical research communications},
  year={2016},
  volume={474 1},
  pages={
          154-160
        }
}
The efficacy of EGFR-tyrosine kinase inhibitors (TKIs) is significantly limited by various resistance mechanisms to those drugs. The resistance to EGFR-TKI is largely divided by two classes; acquired resistance after EGFR-TKI treatment, and primary resistance marked by cancer cell's dependence on other oncogene, such as KRAS. YAP has emerged as critical oncogene in conferring drug resistance against targeted therapy. In this study, we evaluated the role of YAP in primary and acquired EGFR-TKI… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

A randomized

  • H. Yoshioka, K. Azuma, +14 authors K. Nakagawa
  • double-blind, placebo-controlled, phase III trial…
  • 2015

AZD9291

  • D. A. Cross, S. E. Ashton, +23 authors W. Pao
  • an irreversible EGFR TKI, overcomes T790Mmediated…
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…